---

Brought to you by RivalSense - an AI tool for monitoring any company.

RivalSense tracks the most important product launches, fundraising news, partnerships, hiring activities, pricing changes, tech news, vendors, corporate filings, media mentions, and other developments of companies you're following 💡

---

CEPI

🌎 cepi.net

CEPI, the Coalition for Epidemic Preparedness Innovations, is a global partnership established in 2017 to accelerate the development of vaccines against future epidemics. It focuses on developing vaccines for various pathogens, including Ebola, Lassa virus, and COVID-19, and aims to compress vaccine development timelines to 100 days. CEPI also invests in platform technologies for rapid vaccine development and ensures fair allocation of vaccines worldwide through initiatives like COVAX.

---

CEPI - Latest News and Updates

• CEPI and the U.S. International Development Finance Corporation announced a collaboration to enhance global health security by investing in vaccine initiatives and exploring pandemic financing tools.
• CEPI provided funding to Christian Drosten, a researcher at Charité, along with other organizations like WHO and the Bill and Melinda Gates Foundation.
• CEPI is developing a button that could enable vaccines to be mailed and self-administered like a sticker to address clinician shortages and needle phobia.
• CEPI's recent manuscript on Mpox outbreak response was published in Nature Medicine, detailing their preparedness strategies and assay development.
• CEPI is hiring for roles focused on innovative technologies to rapidly respond to disease outbreaks, with applications due by February 9.

• Emma Wheatley from CEPI will join a discussion with Michelle McMurry-Heath, Jennifer Nuzzo, and Jaime Yassif at the JPMorgan Health Care Conference on January 16.
• CEPI has been supplied with antibody testing kits by Zalgen, which also provides diagnostics and reagents to CEPI-funded vaccine developers.

---

Sign up to receive regular updates

If you liked the insights, consider following your own companies of interest. Receive weekly insights directly to your inbox using RivalSense.